Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Valneva Se ADR (VALN)

Valneva Se ADR (VALN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 321,738
  • Shares Outstanding, K 81,247
  • Annual Sales, $ 166,360 K
  • Annual Income, $ -109,780 K
  • EBIT $ 74 M
  • EBITDA $ -70 M
  • 60-Month Beta 1.98
  • Price/Sales 2.07
  • Price/Cash Flow N/A
  • Price/Book 1.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.27
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +58.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.82 +2.62%
on 12/02/24
5.28 -25.76%
on 11/14/24
-0.87 (-18.16%)
since 11/12/24
3-Month
3.82 +2.62%
on 12/02/24
6.55 -40.11%
on 09/26/24
-3.06 (-43.84%)
since 09/12/24
52-Week
3.82 +2.62%
on 12/02/24
10.93 -64.13%
on 12/14/23
-6.73 (-63.19%)
since 12/12/23

Most Recent Stories

More News
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop

The company is doubling down on its vaccine success.

PFE : 25.29 (+0.24%)
BNTX : 120.96 (+1.36%)
VALN : 3.92 (-1.01%)
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri®...

VALN : 3.92 (-1.01%)
VBIV : 0.0653 (-50.87%)
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524),...

VALN : 3.92 (-1.01%)
PFE : 25.29 (+0.24%)
Why Dynavax Crushed the Market on Thursday

Its partner's coronavirus vaccine comes one important step closer to approval in Europe.

DVAX : 13.16 (+1.94%)
VALN : 3.92 (-1.01%)
The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right Now

Markets looked poised for a rebound on Tuesday.

COMP : 7.06 (-0.42%)
$DOWI : 44,084.44 (-0.15%)
$SPX : 6,076.70 (-0.12%)
$NASX : 20,012.13 (-0.11%)
SHOP : 116.72 (-0.55%)
VALN : 3.92 (-1.01%)
PFE : 25.29 (+0.24%)
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated...

VALN : 3.92 (-1.01%)
PFE : 25.29 (+0.24%)
Why Dynavax Stock Blasted 16% Higher Today

One of its vaccine partners had some encouraging regulatory news to report.

DVAX : 13.16 (+1.94%)
VALN : 3.92 (-1.01%)
Why Dynavax Stock Won on a Losing Monday for the Market

The company earns an Emergency Use Authorization from a well-off Middle Eastern country.

PFE : 25.29 (+0.24%)
DVAX : 13.16 (+1.94%)
VALN : 3.92 (-1.01%)
Valneva SE (VALN) Q1 2022 Earnings Call Transcript

VALN earnings call for the period ending March 31, 2022.

VALN : 3.92 (-1.01%)
Why Pfizer Stock Rose Today While the Market Tanked

The company and its partner Valneva had some good news to report.

PFE : 25.29 (+0.24%)
VALN : 3.92 (-1.01%)

Business Summary

Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.

See More

Key Turning Points

3rd Resistance Point 4.53
2nd Resistance Point 4.41
1st Resistance Point 4.18
Last Price 3.92
1st Support Level 3.84
2nd Support Level 3.73
3rd Support Level 3.50

See More

52-Week High 10.93
Fibonacci 61.8% 8.21
Fibonacci 50% 7.37
Fibonacci 38.2% 6.54
Last Price 3.92
52-Week Low 3.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar